Protein kinase CK2 potentiates translation efficiency by phosphorylating eIF3j at Ser127

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 7, 2015, Pages 1693-1701

  Borgo, Christian ^a   Franchin, Cinzia ^a   Salizzato, Valentina ^a   Cesaro, Luca ^a   Arrigoni, Giorgio ^a   Matricardi, Laura ^b   Pinna, Lorenzo A ^a   Donella Deana, Arianna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

EIF3 assembly; EIF3 complex; EIF3j phosphorylation; Protein kinase CK2; Translation initiation activation

Indexed keywords

CASEIN KINASE II; INITIATION FACTOR 3; INITIATION FACTOR 3J; SERINE; SILMITASERTIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 5-(3-CHLOROPHENYLAMINO)BENZO(C)(2,6)NAPHTHYRIDINE-8-CARBOXYLIC ACID; NAPHTHYRIDINE DERIVATIVE; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN SUBUNIT;

ARTICLE; CONTROLLED STUDY; DISSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RIBOSOME SUBUNIT; RNA INTERFERENCE; TRANSLATION INITIATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME SPECIFICITY; GENE SILENCING; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PHOSPHORYLATION; PROTEIN SUBUNIT;

EUKARYOTA; MAMMALIA;

CASEIN KINASE II; EUKARYOTIC INITIATION FACTOR-3; GENE SILENCING; HEK293 CELLS; HELA CELLS; HUMANS; MUTATION; NAPHTHYRIDINES; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN SUBUNITS; SUBSTRATE SPECIFICITY;

EID: 84928248292     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.04.004     Document Type: Article

References (48)

1. Hinnebusch A.G. eIF3: a versatile scaffold for translation initiation complexes. Trends Biochem. Sci. 2006, 31:553-562. 10.1016/j.tibs.2006.08.005.
2. Wagner S., Herrmannová A., Malík R., Peclinovská L., Valášek L.S. Functional and biochemical characterization of human eukaryotic translation initiation factor 3 in living cells. Mol. Cell. Biol. 2014, 34:3041-3052. 10.1128/MCB.00663-14.
3. Siridechadilok B., Fraser C.S., Hall R.J., Doudna J.A., Nogales E. Structural roles for human translation factor eIF3 in initiation of protein synthesis. Science 2005, 310:1513-1515. 10.1126/science.1118977.
4. Masutani M., Sonenberg N., Yokoyama S., Imataka H. Reconstitution reveals the functional core of mammalian eIF3. EMBO J. 2007, 26:3373-3383. 10.1038/sj.emboj.7601765.
5. Querol-Audi J., Sun C., Vogan J.M., Smith M.D., Gu Y., Cate J.H.D., et al. Architecture of human translation initiation factor 3. Structure 2013, 21:920-928. 10.1016/j.str.2013.04.002.
6. Holz M.K., Ballif B.A., Gygi S.P., Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123:569-580. 10.1016/j.cell.2005.10.024.
7. Harris T.E., Chi A., Shabanowitz J., Hunt D.F., Rhoads R.E., Lawrence J.C. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J. 2006, 25:1659-1668. 10.1038/sj.emboj.7601047.
8. Fraser C.S., Lee J.Y., Mayeur G.L., Bushell M., Doudna J.A., Hershey J.W.B. The j-subunit of human translation initiation factor eIF3 is required for the stable binding of eIF3 and its subcomplexes to 40S ribosomal subunits in vitro. J. Biol. Chem. 2004, 279:8946-8956. 10.1074/jbc.M312745200.
9. Miyamoto S., Patel P., Hershey J.W.B. Changes in ribosomal binding activity of eIF3 correlate with increased translation rates during activation of T lymphocytes. J. Biol. Chem. 2005, 280:28251-28264. 10.1074/jbc.M414129200.
10. Elantak L., Wagner S., Herrmannová A., Karásková M., Rutkai E., Lukavsky P.J., et al. The indispensable N-terminal half of eIF3j/HCR1 cooperates with its structurally conserved binding partner eIF3b/PRT1-RRM and with eIF1A in stringent AUG selection. J. Mol. Biol. 2010, 396:1097-1116. 10.1016/j.jmb.2009.12.047.
11. Nielsen K.H., Valásek L., Sykes C., Jivotovskaya A., Hinnebusch A.G. Interaction of the RNP1 motif in PRT1 with HCR1 promotes 40S binding of eukaryotic initiation factor 3 in yeast. Mol. Cell. Biol. 2006, 26:2984-2998. 10.1128/MCB.26.8.2984-2998.2006.
12. Fraser C.S., Berry K.E., Hershey J.W.B., Doudna J.A. eIF3j is located in the decoding center of the human 40S ribosomal subunit. Mol. Cell 2007, 26:811-819. 10.1016/j.molcel.2007.05.019.
13. Sokabe M., Fraser C.S. Human eukaryotic initiation factor 2 (eIF2)-GTP-Met-tRNAi ternary complex and eIF3 stabilize the 43S preinitiation complex. J. Biol. Chem. 2014, 289:31827-31836. 10.1074/jbc.M114.602870.
14. Pisarev A.V., Hellen C.U.T., Pestova T.V. Recycling of eukaryotic posttermination ribosomal complexes. Cell 2007, 131:286-299. 10.1016/j.cell.2007.08.041.
15. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 2003, 369:1-15. 10.1042/BJ20021469.
16. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17:349-368. 10.1096/fj.02-0473rev.
17. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2-a key suppressor of apoptosis. Adv. Enzym. Regul. 2008, 48:179-187. 10.1016/j.advenzreg.2008.04.002.
18. St-Denis N.A., Litchfield D.W. Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell. Mol. Life Sci. 2009, 66:1817-1829. 10.1007/s00018-009-9150-2.
19. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim. Biophys. Acta 2010, 1804:499-504. 10.1016/j.bbapap.2009.07.018.
20. Cozza G., Mazzorana M., Papinutto E., Bain J., Elliott M., di Maira G., et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 2009, 421:387-395. 10.1042/BJ20090069.
21. Ruzzene M., Di Maira G., Tosoni K., Pinna L.A. Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol. 2010, 484:495-514. 10.1016/B978-0-12-381298-8.00024-1.
22. Venerando A., Franchin C., Cant N., Cozza G., Pagano M.A., Tosoni K., et al. Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation. PLoS ONE 2013, 8:e74232. 10.1371/journal.pone.0074232.
23. Thingholm T.E., Jørgensen T.J.D., Jensen O.N., Larsen M.R. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006, 1:1929-1935. 10.1038/nprot.2006.185.
24. Salvi M., Trashi E., Cozza G., Franchin C., Arrigoni G., Pinna L.A. Investigation on PLK2 and PLK3 substrate recognition. Biochim. Biophys. Acta 2012, 1824:1366-1373. 10.1016/j.bbapap.2012.07.003.
25. Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O'Brien S.E., et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010, 70:10288-10298. 10.1158/0008-5472.CAN-10-1893.
26. Meggio F., Donella Deana A., Ruzzene M., Brunati A.M., Cesaro L., Guerra B., et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 1995, 234:317-322.
27. Salvi M., Sarno S., Cesaro L., Nakamura H., Pinna L.A. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim. Biophys. Acta 2009, 1793:847-859. 10.1016/j.bbamcr.2009.01.013.
28. Girardi C., James P., Zanin S., Pinna L.A., Ruzzene M. Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions. Biochim. Biophys. Acta 2014, 1843:1865-1874. 10.1016/j.bbamcr.2014.04.020.
29. Perrotti D., Turturro F., Neviani P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ. 2005, 12:534-540. 10.1038/sj.cdd.4401606.
30. Valásek L., Hasek J., Trachsel H., Imre E.M., Ruis H. The Saccharomyces cerevisiae HCR1 gene encoding a homologue of the p35 subunit of human translation initiation factor 3 (eIF3) is a high copy suppressor of a temperature-sensitive mutation in the Rpg1p subunit of yeast eIF3. J. Biol. Chem. 1999, 274:27567-27572.
31. Issinger O.G., Benne R., Hershey J.W., Traut R.R. Phosphorylation in vitro of eukaryotic initiation factors IF-E2 and IF-E3 by protein kinases. J. Biol. Chem. 1976, 251:6471-6474.
32. Pinna L.A. A historical view of protein kinase CK2. Cell. Mol. Biol. Res. 1994, 40:383-390.
33. Dennis M.D., Person M.D., Browning K.S. Phosphorylation of plant translation initiation factors by CK2 enhances the in vitro interaction of multifactor complex components. J. Biol. Chem. 2009, 284:20615-20628. 10.1074/jbc.M109.007658.
34. Farley A.R., Powell D.W., Weaver C.M., Jennings J.L., Link A.J. Assessing the components of the eIF3 complex and their phosphorylation status. J. Proteome Res. 2011, 10:1481-1494. 10.1021/pr100877m.
35. Dephoure N., Zhou C., Villén J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., et al. A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10762-10767. 10.1073/pnas.0805139105.
36. Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., et al. Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci. Signal. 2009, 2:ra46. 10.1126/scisignal.2000007.
37. Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal. 2010, 3:ra3. 10.1126/scisignal.2000475.
38. Weber C., Schreiber T.B., Daub H. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J. Proteome 2012, 75:1343-1356. 10.1016/j.jprot.2011.11.004.
39. Hershey J.W.B. Regulation of protein synthesis and the role of eIF3 in cancer. Braz. J. Med. Biol. Res. 2010, 43:920-930.
40. Marchione R., Leibovitch S.A., Lenormand J.-L. The translational factor eIF3f: the ambivalent eIF3 subunit. Cell. Mol. Life Sci. 2013, 70:3603-3616. 10.1007/s00018-013-1263-y.
41. Zhang L., Smit-McBride Z., Pan X., Rheinhardt J., Hershey J.W.B. An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. J. Biol. Chem. 2008, 283:24047-24060. 10.1074/jbc.M800956200.
42. Goh S.-H., Hong S.-H., Hong S.-H., Lee B.-C., Ju M.-H., Jeong J.-S., et al. eIF3m expression influences the regulation of tumorigenesis-related genes in human colon cancer. Oncogene 2011, 30:398-409. 10.1038/onc.2010.422.
43. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266. 10.1038/nrc2824.
44. Borgo C., Cesaro L., Salizzato V., Ruzzene M., Massimino M.L., Pinna L.A., et al. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. Mol. Oncol. 2013, 7:1103-1115. 10.1016/j.molonc.2013.08.006.
45. Sokabe M., Fraser C.S., Hershey J.W.B. The human translation initiation multi-factor complex promotes methionyl-tRNAi binding to the 40S ribosomal subunit. Nucleic Acids Res. 2012, 40:905-913. 10.1093/nar/gkr772.
46. Hinnebusch A.G. The scanning mechanism of eukaryotic translation initiation. Annu. Rev. Biochem. 2014, 83:779-812. 10.1146/annurev-biochem-060713-035802.
47. Llorens F., Duarri A., Sarró E., Roher N., Plana M., Itarte E. The N-terminal domain of the human eIF2beta subunit and the CK2 phosphorylation sites are required for its function. Biochem. J. 2006, 394:227-236. 10.1042/BJ20050605.
48. Homma M.K., Wada I., Suzuki T., Yamaki J., Krebs E.G., Homma Y. CK2 phosphorylation of eukaryotic translation initiation factor 5 potentiates cell cycle progression. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15688-15693. 10.1073/pnas.0506791102.